Subanalyses of Mobility and Monarch studies show that #RA patients with highest tertiles of IL-6 (and CRP) had more disease activity, more Xray damage and better responses (less Xray change) to Sarilumab (vs Adalimumab or MTX). https://t.co/5mTePETFAQ